$2.78
-0.11 (-3.81%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AEMD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 2 tracked-famous managers (CITADEL ADVISORS LLC, JANE STREET GROUP, LLC) · FINRA short interest 1.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Hemopurifier Plus Pembrolizumab in Head and Neck CancerNCT04453046Safety as measured by adverse eventsOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Lack of Eligible subjects at study site | Device: Hemopurifier · Drug: Pembrolizumab 200mg IV | Squamous Cell Carcinoma of the Head and Neck | 2 | 2022-11-14actual | 2022-12-20 |
| Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® DeviceNCT04595903Incidence of treatment emergent adverse eventsOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Lack of eligible COVID-ICU patients | Device: Hemopurifier | COVID-19 | 1 | 2022-11-14actual | 2022-12-20 |
| Safety Study of the Aethlon HemopurifierNCT02215902Rate of adverse eventsOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Adequate safety data has been accumulated and the # of patients meeting inclusion criteria has diminished. | Device: Affinity plasmapheresis | End Stage Renal Disease, Hepatitis C Infection | 8 | 2017-03-10actual | 2017-03-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19